Alysse Fazal

JUN 26, 2026 · JOURNAL ARTICLE

Silencing Triglycerides: The Clinical Impact of Plozasiran and apoC-III Inhibition in Severe Hypertriglyceridemia

Journal of Cardiovascular Pharmacology

Phase III trial demonstrates robust triglyceride reduction and favorable safety in a specific high-risk population, but lacks hard clinical outcome data and generalizability beyond familial chylomicronemia syndrome.